trending Market Intelligence /marketintelligence/en/news-insights/trending/e_vFLipKeKvNK8gPisJj9Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Biogen to buy back $5B of common stock

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Biogen to buy back $5B of common stock

Biogen Inc.'s board authorized to repurchase up to $5 billion of the company's common stock.

The 2019 share repurchase program has no expiration date, the Cambridge, Mass.-based biotechnology company said.

Biogen, which focuses on neurodegenerative diseases, said the new repurchase program is in addition to the about $1.7 billion remaining under a $3.5 billion buyback program launched in August 2018.

Biogen stocks dropped more than 29% after news that the company and Japan's Eisai Co. Ltd. will be discontinuing two late-stage clinical trials of their Alzheimer's drug aducanumab. Biogen shares fell to $226.88 as of the close of U.S. trading March 21, down 29.23%.